New data highlights include: - Phase 3 open-label extension study data for growth hormone-deficient children treated for 2.5 years with TransConTM…
In accordance with Section 32 of the Danish Capital Markets Act, GN Store Nord is required to publish the total…
Oticon demonstrates its unwavering prowess in product design, achieving not one, but two internationally recognised awards for good design for…
Caution: The iLet® Bionic Pancreas is an investigational device limited by Federal (or United States) law to investigational use. Not…
PRESS RELEASE April 30, 2022 Saniona (OMX: SANION), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that the…
IRVINE, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet…
TORONTO, April 29, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical…
NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER UNITED STATES WIRE SERVICES Company reports strong revenue growth of 22%…
First novel, nonstimulant option for adults with ADHD in 20 yearsADHD affects an estimated 10 million adults in the U.S.ROCKVILLE,…
ORGOVYX® is the first and only oral androgen deprivation therapy for advanced hormone-sensitive prostate cancer in EuropeMyovant expects to secure…